Northern Trust Corp Protagonist Therapeutics, Inc Transaction History

Northern Trust Corp

  • $600 Billion
  • Q3 2024

A detailed history of Northern Trust Corp transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Northern Trust Corp holds 580,089 shares of PTGX stock, worth $23.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
580,089
Previous 508,459 14.09%
Holding current value
$23.6 Million
Previous $17.6 Million 47.97%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
BUY
$33.72 - $47.33 $2.42 Million - $3.39 Million
71,630 Added 14.09%
580,089 $26.1 Million
Q2 2024

Aug 14, 2024
SELL
$24.66 - $34.8 $753,017 - $1.06 Million
-30,536 Reduced 5.67%
508,459 $17.6 Million
Q1 2024

May 14, 2024
SELL
$21.79 - $32.15 $242,827 - $358,279
-11,144 Reduced 2.03%
538,995 $15.6 Million
Q4 2023

Feb 13, 2024
SELL
$14.05 - $23.44 $176,313 - $294,148
-12,549 Reduced 2.23%
550,139 $12.6 Million
Q3 2023

Nov 13, 2023
BUY
$16.68 - $23.66 $409,710 - $581,160
24,563 Added 4.56%
562,688 $9.39 Million
Q2 2023

Aug 11, 2023
BUY
$18.02 - $29.36 $2.08 Million - $3.39 Million
115,489 Added 27.33%
538,125 $14.9 Million
Q1 2023

May 15, 2023
BUY
$10.78 - $25.38 $43,432 - $102,256
4,029 Added 0.96%
422,636 $9.72 Million
Q4 2022

Feb 13, 2023
BUY
$7.36 - $11.17 $6,064 - $9,204
824 Added 0.2%
418,607 $4.57 Million
Q3 2022

Nov 14, 2022
SELL
$7.86 - $11.71 $44,574 - $66,407
-5,671 Reduced 1.34%
417,783 $3.52 Million
Q2 2022

Aug 12, 2022
SELL
$7.06 - $25.52 $82,065 - $296,644
-11,624 Reduced 2.67%
423,454 $3.35 Million
Q1 2022

May 13, 2022
SELL
$23.34 - $36.08 $474,572 - $733,614
-20,333 Reduced 4.46%
435,078 $10.3 Million
Q4 2021

Feb 08, 2022
SELL
$17.63 - $37.1 $27,608 - $58,098
-1,566 Reduced 0.34%
455,411 $15.6 Million
Q3 2021

Nov 15, 2021
BUY
$12.95 - $49.69 $160,476 - $615,758
12,392 Added 2.79%
456,977 $8.1 Million
Q2 2021

Aug 13, 2021
BUY
$25.57 - $44.88 $743,371 - $1.3 Million
29,072 Added 7.0%
444,585 $20 Million
Q1 2021

May 12, 2021
BUY
$19.02 - $31.15 $224,359 - $367,445
11,796 Added 2.92%
415,513 $10.8 Million
Q4 2020

Feb 11, 2021
BUY
$18.49 - $25.13 $355,007 - $482,496
19,200 Added 4.99%
403,717 $8.14 Million
Q3 2020

Nov 16, 2020
BUY
$15.19 - $22.4 $891,896 - $1.32 Million
58,716 Added 18.02%
384,517 $7.52 Million
Q2 2020

Aug 14, 2020
BUY
$6.19 - $18.84 $432,191 - $1.32 Million
69,821 Added 27.28%
325,801 $5.75 Million
Q1 2020

May 14, 2020
BUY
$5.4 - $9.22 $55,641 - $95,002
10,304 Added 4.19%
255,980 $1.81 Million
Q4 2019

Feb 14, 2020
SELL
$4.69 - $13.45 $4,375 - $12,548
-933 Reduced 0.38%
245,676 $1.73 Million
Q3 2019

Nov 13, 2019
BUY
$9.41 - $16.56 $1.66 Million - $2.92 Million
176,269 Added 250.6%
246,609 $2.96 Million
Q2 2019

Aug 13, 2019
BUY
$8.98 - $12.96 $282,663 - $407,941
31,477 Added 80.99%
70,340 $851,000
Q1 2019

May 13, 2019
BUY
$6.5 - $13.77 $27,553 - $58,371
4,239 Added 12.24%
38,863 $489,000
Q4 2018

Feb 12, 2019
BUY
$6.3 - $10.44 $32,029 - $53,076
5,084 Added 17.21%
34,624 $234,000
Q3 2018

Nov 14, 2018
SELL
$6.82 - $11.26 $3,764 - $6,215
-552 Reduced 1.83%
29,540 $304,000
Q2 2018

Aug 14, 2018
SELL
$5.99 - $9.1 $581,125 - $882,845
-97,016 Reduced 76.33%
30,092 $202,000
Q1 2018

May 09, 2018
SELL
$8.46 - $23.08 $1,522 - $4,154
-180 Reduced 0.14%
127,108 $1.09 Million
Q4 2017

Feb 14, 2018
BUY
$14.47 - $20.8 $429,411 - $617,260
29,676 Added 30.4%
127,288 $2.65 Million
Q3 2017

Nov 13, 2017
BUY
$10.61 - $17.98 $1.04 Million - $1.76 Million
97,612
97,612 $1.73 Million

Others Institutions Holding PTGX

# of Institutions
247
Shares Held
56.4M
Call Options Held
76.3K
Put Options Held
114K
View Full List

About Protagonist Therapeutics, Inc

PTGX Quotes by TradingView
  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email